Bio-Rad Laboratories, Inc. Revenue 2008–2025
Bio-Rad Laboratories, Inc. reported $2.58B of revenue for fiscal 2025. That was 0.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +1.5%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $2.58B | +0.7% |
| FY 2024 | $2.57B | -3.9% |
| FY 2023 | $2.67B | -4.7% |
| FY 2022 | $2.80B | -4.1% |
| FY 2021 | $2.92B | +14.8% |
| FY 2020 | $2.55B | +10.1% |
| FY 2019 | $2.31B | +1.0% |
| FY 2018 | $2.29B | +6.0% |
| FY 2017 | $2.16B | +4.4% |
| FY 2016 | $2.07B | +2.4% |
| FY 2015 | $2.02B | -7.2% |
| FY 2014 | $2.18B | +2.0% |
| FY 2013 | $2.13B | +3.1% |
| FY 2012 | $2.07B | -0.2% |
| FY 2011 | $2.07B | +7.6% |
| FY 2010 | $1.93B | +8.0% |
| FY 2009 | $1.78B | +1.1% |
| FY 2008 | $1.76B | — |
Source: Bio-Rad Laboratories, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BIO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Bio-Rad Laboratories, Inc. reported $2.58B of revenue for fiscal 2025. That was 0.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +1.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Bio-Rad Laboratories, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBio-Rad Laboratories, Inc. — frequently asked questions
What is Bio-Rad Laboratories, Inc.'s revenue?
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $2.58B for fiscal year 2025, per its SEC filings.
How has Bio-Rad Laboratories, Inc.'s revenue changed over time?
Between fiscal 2008 and 2025, BIO's revenue grew at roughly 2.3% per year (compound annual rate), from $1.76B to $2.58B.
Where does this data come from?
Figures are computed from Bio-Rad Laboratories, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.